Potential effects of COVID-19 on reproductive systems and fertility; assisted reproductive technology guidelines and considerations: a review

WY Lee, Alex Mok, Jacqueline PW Chung *

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) employs the angiotensin-converting enzyme 2 (ACE2) receptor in the renin-angiotensin system for viral entry. The ACE2 receptor is present in both female and male reproductive systems, and reports of multi-organ involvement have led to uncertainty regarding its effects on the reproductive system and fertility. We review the existing literature regarding the function of ACE2 and the renin-angiotensin system in the female and male reproductive systems to postulate the possible implications of SARS-CoV-2 regarding fertility. Because of the presence of ACE2 in the ovaries, SARS-CoV-2 infection may disrupt ovarian function and hence oocyte quality. Higher expression of ACE2 in the endometrium with age and during the secretory phase raises concern about increased susceptibility to infection during periods of high ACE2 expression. The possibility of vertical transmission and the presence of ACE2 in the placenta and during pregnancy are also discussed. The presence of SARS-CoV-2 RNA in semen is controversial, but impaired semen quality has been found in men with moderate coronavirus disease 2019 infection.

Evidence of orchitis and hormonal changes seen in male coronavirus disease 2019 infection may lead to infertility. The implications of these effects on assisted reproductive technology (ART) outcomes are also explored. The ART guidelines from different fertility societies for the management of patients treated with ART are provided. The importance of prioritising ‘time-sensitive’ patients for ART, counselling patients about the uncertainty and risks of ART, and pregnancy during the pandemic is discussed. Recommendations are also provided for infection control and safe regulation of ART centres and laboratories.

Introduction
Coronavirus disease 2019 (COVID-19) is a serious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The SARS-CoV-2 employs the angiotensin-converting enzyme 2 (ACE2) receptor in the renin-angiotensin system (RAS) for viral entry.¹ The ACE2 receptor is present in the reproductive system, and reports of multi-organ involvement have led to uncertainty regarding COVID-19’s effects on the reproductive system and fertility.² We reviewed the existing literature regarding the function of ACE2 and RAS in the reproductive system. Our aim was to postulate and understand the effects of SARS-CoV-2 infection on fertility and assisted reproductive technology (ART) outcomes through RAS, so as to prompt further quantitative research. We also discuss guidelines on the management of patients treated with ART and safe regulation of ART centres/laboratories to improve infection control during the pandemic.

Relationships between severe acute respiratory syndrome coronavirus, angiotensin-converting enzyme 2 receptor, and renin-angiotensin system
The SARS-CoV-2 virus enters the body via binding to ACE2 expressed on target host cells.¹ The spike protein of SARS-CoV-2 attaches to this receptor, similarly to SARS-CoV-1, to facilitate endocytosis and cellular infection.¹ The Figure illustrates the role of ACE2 in RAS.¹³

The angiotensin II (Ang II) and Ang-(1-7) hormones have opposing effects. Whereas Ang II is pro-inflammatory, pro-fibrotic, and pro-apoptotic with tissue remodelling properties, Ang-(1-7) is anti-inflammatory and anti-fibrotic.³ In other words, ACE1 and ACE2 counteract each other, and their roles are essential in balancing RAS.

Infection with SARS-CoV-2 causes reduced ACE2 activity and downregulation. This increases...
circulating Ang II in patients with SARS-CoV-2 infection.4,5 This explains the inflammatory and fibrotic effects seen in COVID-19 lung injury.4,5

There are increasing reports of multi-organ involvement, with SARS-CoV-2 found in blood, stools, urine, and saliva.2,3,6 This suggests that ACE2 in different organ systems may contribute to the pathophysiology of COVID-19 dissemination through viraemia.1,3 As ACE2 is also present in the testes and female reproductive system, it is speculated that the reproductive system may also be affected by SARS-CoV-2.7,8 We analysed the local RAS and its function in the reproductive system to postulate how COVID-19 may affect female and male steroidogenesis, germ cells, and reproductive health.8,9

Influence of coronavirus disease 2019 on the female reproductive system

Ovarian and follicular development

Although ACE2 is ubiquitous in the female reproductive system, it is found mostly in the ovaries.8–10 All other components of RAS are also found in the ovaries, making them potential targets for damage by SARS-CoV-2.8–10

Angiotensin II, found predominantly in granulosa cells, regulates follicular development, oocyte maturation, and ovulation.8,9 It is involved in sex hormone secretion, follicular atresia, and ovarian and corpus luteum angiogenesis.8,10 Angiotensin-(1-7), presenting in theca-interstitial cells, is involved in steroidogenesis, oocyte meiosis resumption, follicular development, atresia, and enhancing ovulation.8,9 The ACE2, Ang-(1-7), and Mas-receptor are found in all stages of follicular development, and studies in rats demonstrated that their expression was altered by gonadotropin, implicating the pathway’s potential role in fertility.8,9 Furthermore, Ang-(1-7) levels in follicular fluid collected during ovarian stimulation for in vitro fertilisation positively correlate with the proportion of mature oocytes.11 Combined with animal studies proving a causal relationship between Ang-(1-7) and oocyte maturation, the evidence indicates that Ang-(1-7) may be a human oocyte maturation factor.11

The downregulation of ACE2 by SARS-CoV-2 may cause alterations in normal ovarian physiology, such as follicular development and oocyte maturation, impacting oocyte quality and fertility. Oxidative stress is also increased by Ang II as it exerts pro-inflammatory effects.9 This may be detrimental to reproductive ability. Further investigations ought to be conducted to elucidate the full extent of the impact of COVID-19 on reproductive health in women.
to be done to demonstrate whether increased Ang II/Ang II type 1 receptor (AT1R) signalling in SARS-CoV-2 cases affects ovarian physiology and fertility.

Uterus and fallopian tubes

The RAS is present in the uterus, mostly confined to the epithelial and stromal cells of the endometrium.\textsuperscript{8,10,12} Thus, if COVID-19 damages endometrial epithelial cells, it may affect early embryo implantation.\textsuperscript{13} Little research has been done to analyse RAS function in the uterus, but the expression of RAS components fluctuates during the cycle.\textsuperscript{10} The ACE2, Ang-(1-7), and Mas receptor expression are higher in the secretory than the proliferative phase, whereas Ang II and AT1R expression are higher in the proliferative than the secretory phase.\textsuperscript{8,10,12} This raises concern about whether the endometrium is more susceptible to SARS-CoV-2 during the secretory phase. Nevertheless, a study by Henarejos-Castillo et al\textsuperscript{14} revealed lower overall endometrial susceptibility to SARS-CoV-2. They also reported a positive correlation between age and endometrial infection in older women.\textsuperscript{14,15} A normal level of Ang II expression is crucial to maintaining regular menstrual cycles and endometrial activity, as it facilitates regeneration of blood vessels and the endometrium and initiates menstruation.\textsuperscript{8} Endometrial and myometrial activities including endometrial regeneration, proliferation, fibrosis, and stromal proliferation are regulated by the intricate balance of Ang II and Ang-(1-7)\textsuperscript{8,10,12} in the uterus, ie, stimulated by Ang II and inhibited by Ang-(1-7).\textsuperscript{8} Infection of the uterus with SARS-CoV-2 may severely disrupt such balance. Disruption of Ang II levels has been found to be related to dysfunctional uterine bleeding associated with hyperplastic endometrium.\textsuperscript{8} Whether this has any correlation to altered blood flow and increased risk of miscarriage is unknown and requires further quantitative research.

In the fallopian tubes, Ang II has been found in the endothelium and stroma.\textsuperscript{10} Both AT1R and AT2R are present in the epithelium.\textsuperscript{8,10,12} Similarly to Ang II/AT1R expression fluctuation in the uterus, AT1R expression also changes throughout the cycle (ie, higher in the proliferative and lower in the secretory phase).\textsuperscript{12} The function of Ang II remains unclear, but one study reported that it stimulates the ciliary beat frequency in epithelial cells.\textsuperscript{8,10,12}

Placenta and pregnancy

Studies regarding vertical transmission are controversial, and there is insufficient evidence to confirm transplacental COVID-19 infection. One study detected SARS-CoV-2 in the placental and fetal membranes, but the infants tested negative in the first 5 days of life.\textsuperscript{16} Possible contamination sources include maternal blood, vaginal secretions, and amniotic fluid.\textsuperscript{16} Nevertheless, the risk of placental/ amniotic sac COVID-19 infection still cannot be ruled out, warranting further research.

Expression of ACE2 is higher in the placenta than in the lungs,\textsuperscript{8} further substantiating the risk of placental SARS-CoV-2 infection. Low placental ACE2 and Ang-(1-7) have been reported to be associated with intrauterine growth restriction, an outcome that has also been seen in pregnant patients with COVID-19.\textsuperscript{8} This signifies that placental COVID-19 infection may have severe implications for pregnancy outcomes.

Local RAS expression has been identified in the placenta and cell lines as early as 6 weeks of gestation, but its function remains ambiguous.\textsuperscript{10} One study reported possible RAS involvement in trophoblast invasion and angiogenesis and suggested that local RAS alteration may contribute to abnormal uteroplacental perfusion, leading to pre-eclampsia.\textsuperscript{10}

The maternal decidua and pericytes of endometrial spiral arteries also contain Ang II. Angiotensin II type 1 receptor is found in maternal decidua, cytotrophoblasts, syncytiotrophoblasts, and fetal capillaries,\textsuperscript{10} and Ang-(1-7) and ACE2 are localised in syncytiotrophoblasts, cytotrophoblasts, and the endothelium and vascular smooth muscle of primary and secondary villi.\textsuperscript{8,10} Angiotensin-converting enzyme 2 is also localised in invading and intravascular trophoblasts and in decidual cells of maternal stroma.\textsuperscript{8} In the umbilical cord, ACE2 is localised in smooth muscles and the vascular endothelium.\textsuperscript{8} All of these serve as potential SARS-CoV-2 entry points to the placenta.

In addition, RAS expression fluctuates throughout pregnancy.\textsuperscript{10} Whereas AT1R expression increases during gestation and peaks at the end, ACE2 peaks early in gestation.\textsuperscript{8,10} Whether this causes increased susceptibility to placental SARS-CoV-2 infection during early gestation is unknown. The expression of ACE2 also differs in location throughout pregnancy: it appears in the primary and secondary decidual zones, the luminal zone, and the glandular epithelium during early gestation and in the labyrinth placenta and the epithelium of the amniotic and yolk sac during late gestation.\textsuperscript{8}

Implications on outcomes of assisted reproductive technology

Whereas COVID-19 has not yet been reported to damage female fertility, its potential detrimental effects cannot be ignored. If patients who recover from COVID-19 undergo ART, it is unknown whether their oocyte quality, quantity, and other parameters will be affected, nor is the duration of abnormality. Future research should be conducted to assess these parameters.
Influence of coronavirus disease 2019 on the male reproductive system

Angiotensin-converting enzyme 2 receptor in the male reproductive system

Some parts of the testis have been found to contain ACE2 (the spermatogonia, Leydig cells, and Sertoli cells), rendering them potential SARS-CoV-2 targets.9,17 The Leydig cells, Sertoli cells, and seminiferous tubules also contain Ang-(1-7) and Mas receptor.9,17

Infertile men with severely impaired spermatogenesis have lower ACE2, Ang-(1-7), and Mas receptor levels compared with fertile men.9 Men with non-obstructive azoospermia were found to have absence of Ang-(1-7) and Mas receptor in the seminiferous tubules.17 As Leydig cells are responsible for steroidogenesis and secretion, particularly testosterone, ACE2, Ang-(1-7) and Mas expression in Leydig cells strongly suggests their potential roles in the regulation of steroidogenesis and secretion, spermatogenesis, and hence their influence on male fertility.9,17 Therefore, ACE2 downregulation in COVID-19 may impair spermatogenesis and male fertility. Nevertheless, ACE2 knockout mice demonstrated no reduction in fertility, suggesting the possibility of other rescue mechanisms that may compensate for ACE2 loss.9,17

Angiotensin II in the testes inhibits Leydig cells and testosterone production and regulates anion and fluid secretion from the epididymis.18 The increase in Ang II induced by COVID-19 may hypothetically affect these functions.

Positive severe acute respiratory syndrome coronavirus 2 in semen

Presence of SARS-CoV-2 RNA in semen has been controversial among studies. A cross-sectional observational study by Pan et al9 was unable to identify SARS-CoV-2 in semen samples among 34 confirmed cases 1 month after diagnosis. Another study by Li et al20 revealed six cases that were positive for SARS-CoV-2 in semen: four during the acute infection and two during the recovery phase. This raises concern about sexual transmission during the acute and particularly the recovery phase of infection. This may have negative implications on fertility, assisted reproduction, vertical transmission, and fetal development. Abstinence and condoms should be used to reduce the potential risk of sexual transmission until more evidence is available.20

Orchitis in coronavirus infection

Multiple studies have reported a high risk of male patients with COVID-19 developing orchitis-like symptoms, suggesting viral orchitis.17 A histological study of 12 testes of deceased patients with COVID-19 revealed characteristics of viral orchitis, lymphocytic infiltration, seminiferous tubular injury, reduced numbers of Leydig cells, vascular congestion, and extensive germ cell destruction.21 As COVID-19 is associated with coagulopathy, the orchitis could have resulted from vasculitis.21

The possibility of orchitis leading to infertility as a complication of infection with coronaviruses such as SARS-CoV-1 is widely accepted.23,24 Similar to the case in COVID-19, pathology revealed focal testicular atrophy, germ cell destruction with decreased number of spermatozoa, and inflammatory cell infiltrates.17,23,24 Interestingly, SARS-CoV-1 was not identified in the testis; instead, high immunoglobulin G precipitation was detected in the seminiferous epithelium, suggesting that an immune-mediated response was causing the testicular damage, rather than direct testicular infection.17,23,24 Male patients with COVID-19 and high immunoglobulin G titre might also have adverse reproductive effects, possibly caused by anti-sperm antibodies such as antiphospholipid antibodies, which interfere with fertilisation.25

Inflammatory infiltration may disrupt spermatogenesis, impede steroidogenesis, and destroy cells in seminiferous tubules.26 Moreover, SARS-CoV-2 induces oxidative stress via inflammatory responses, which might disrupt the process of spermigenesis and lead to spermatozoa having poorly remodelled chromatin.27 Cytokine release activates a secondary autoimmune response and production of antibodies within the seminiferous tubules, leading to autoimmune orchitis and the presence of antibodies in semen.25,26 The cytokine response may also suppress the hypothalamic-pituitary-gonadal axis, leading to reduction of testosterone and sperm production.25 This is consistent with studies that have revealed reduced serum testosterone in patients with COVID-19.25 Semen analysis and follow-up of patients with orchitis during COVID-19 infection should be conducted to evaluate their reproductive functioning.

Hormonal changes in patients with coronavirus disease 2019: signs of hypogonadism

Multiple studies have revealed significant increases in serum luteinising hormone (LH) and prolactin levels among male patients with COVID-19.28,29 A significant decrease in testosterone to LH ratio and follicle-stimulating hormone to LH ratio were also reported.29 It is postulated that the LH increase in COVID-19 resulted from the early stage of impaired testosterone production and was caused by reduction of Leydig cells. This could have caused negative feedback that stimulated Leydig cells to temporarily increase testosterone production.28 There may be a risk of clinical hypogonadism as
the disease progresses. It is therefore important to perform follow-up with post-recovery patients for at least 3 to 6 months, with serum LH and testosterone-to-LH ratio serving as clinical indicators of primary hypogonadism.

Implications on the outcomes of assisted reproductive technology

Infection and viral-mediated immune response to SARS-CoV-2 may disrupt steroidogenesis and spermatogenesis and destroy cells of the seminiferous tubules. A systematic review on semen analysis by Khalili et al revealed significantly impaired semen quality in patients with moderate active COVID-19 infection compared with mild active infection and a control group. Semen samples of patients with moderate SARS-CoV-2 infection were shown to have significantly lower sperm concentration (P<0.05), lower total number of sperm per ejaculation, lower total number of motile sperm, and lower total number of progressively motile sperm than normal patients. In combination with the risk of sexual transmission, the consideration of deferring conception in recovered patients until more evidence is available should be taken seriously. Sperm donation/cryopreservation of active/recovered COVID-19 patients should be avoided, as many viruses remain viable and infectious when cryopreserved.

Assisted reproductive technology recommendations for patients with coronavirus disease 2019 and the general public during the pandemic

Coronavirus disease 2019 infection and possible outcomes of assisted reproductive technology

In consideration of the lack of legitimate evidence and the fact that the available data are mostly derived from studies with small sample sizes, the risk of serious implications of COVID-19 on fertility cannot be ruled out. Furthermore, fever is common in SARS-CoV-2 infection. In female patients who are undergoing ovarian stimulation for ovulation induction, the risk of coagulopathy in COVID-19 may augment the risk of thromboembolic complications during ovarian stimulation. An individualised approach should be adopted. Anti-Müllerian hormone and antral follicle count should be used to assess ovarian reserve and guide the dosage of gonadotrophins. The gonadotrophin-releasing hormone (GnRH) antagonist protocol (with GnRH agonist triggering oocyte maturation and elective cryopreservation of embryos) is extremely effective at minimising the risk of ovarian hyperstimulation syndrome. Moreover, the risk of coagulopathy in COVID-19 may augment the risk of thromboembolic complications during ovarian stimulation. Other than using GnRH

Guidelines on assisted reproductive technology procedures

Infertility is a time-sensitive disease: the longer it is left untreated, the lower the patient's chances of becoming a biological parent. Previously, fertility societies recommended cessation of all reproductive care except urgent cases. However, as countries around the world begin to successfully mitigate the spread of COVID-19, a new joint statement was released on 29 May 2020 by the American Society for Reproductive Medicine, the European Society of Human Reproduction and Embryology (ESHRE), and the International Federation of Fertility Societies. The statement sanctioned gradual resumption of full reproductive care in areas where COVID-19 has been well controlled. Specific protocols should be enforced regarding screening and management of patients treated with ART during the pandemic. Table 1 provides such guidelines by different fertility societies. The ESHRE guideline is used as a reference point. Other societies' recommendations that are the same as those of ESHRE are omitted, ie, only extra information is added for other societies. Because of the ever-changing nature of this pandemic and the variability of cases between countries, there may be future changes to ART regulations. The most updated country-specific regulations should be followed.

There is an increased risk of lung and kidney complications if patients with COVID-19 develop ovarian hyperstimulation syndrome during ovarian stimulation. An individualised approach should be adopted. Anti-Müllerian hormone and antral follicle count should be used to assess ovarian reserve and guide the dosage of gonadotrophins. The gonadotrophin-releasing hormone (GnRH) antagonist protocol (with GnRH agonist triggering oocyte maturation and elective cryopreservation of embryos) is extremely effective at minimising the risk of ovarian hyperstimulation syndrome. Moreover, the risk of coagulopathy in COVID-19 may augment the risk of thromboembolic complications during ovarian stimulation. Other than using GnRH
agonist in high responders/patients with COVID-19, suggested solutions to reduce thromboembolic risk include segmenting the in vitro fertilisation cycle and administering prophylactic low-molecular-weight heparin.45

Infection control in assisted reproductive technology centres and laboratories

Table 2 lists recommendations for infection control in ART centres and laboratories to help reduce the spread of COVID-19.36,38,43,44,46-49

As SARS-CoV-2 can be present in semen, strict protective protocols should be implemented in specimen handling to avoid spillage/exposure.50 If the operator becomes infected, cryopreserved semen samples handled by the operator should be tested via polymerase chain reaction.18 The viral titre of COVID-19-positive semen should be kept at the lowest possible level.51 For gametes/embryos, repeated washing should be done to dilute out any viral contaminants.51

Identification of ‘time-sensitive’ patients for assisted reproductive technology

With the gradual resumption of reproductive services, it is crucial to identify and prioritise patients who have a low prognosis of ART success and whose fertility potential deteriorates rapidly.43,47 Stratifying patients according to Poseidon groups, patients in Poseidon groups 2 and 4 (advanced maternal age with normal/reduced ovarian reserve) should be prioritised, followed by group 3 (age <35 years but with reduced ovarian reserve).47 In male patients who undergo medical treatment to improve sperm quality and quantity, their ‘fertility window’ is short and transient. Sperm analysis and banking should be done as soon as possible to increase their prospects of biological parenthood.

| TABLE 1. Guidelines for screening and management of patients treated with assisted reproductive technology |
|--------------------------------------------------|--------------------------------------------------|
| **Already started cycles** | **Planned cycles/pregnancy** |
| **The European Society of Human Reproduction and Embryology**<sup>38</sup> (updated 14 Oct 2020) | - Follow standard procedures unless changes occur between ovulation trigger and oocyte retrieval. - If positive triage, run SARS-CoV-2 IgM/IgG and/or reverse transcription polymerase chain reaction test. Decide to continue/defer based on result. - If test is positive before ovulation trigger/embryo thawing, defer treatment. - If a potentially positive patient must continue treatment (oncological patient or high-risk OHSS), the following should be implemented: o Filtering facepiece with 2 or 3 masks o Gowning o COVID-19 specific disinfection of all areas after procedure - If patient/partner symptomatic after oocyte retrieval or suspected of/positive during embryo culture, adopt freeze-all policy. - ET only for low-risk/asymptomatic cases. | - All patients can choose to continue/postpone ART. |
| **The American Society for Reproductive Medicine**<sup>39</sup> (8 Sep 2020) | - For donor/gestational carrier: defer oocyte retrieval and ET if positive/symptomatic during stimulation/ before ET. - Serology testing for SARS-CoV-2 in all patients undergoing surgery. | |
| **The Association of Reproductive and Clinical Scientists and British Fertility Society**<sup>40</sup> (6 May 2020) | - For patient/donor suspected of/positive after ovulatory trigger, risk assessment should be done to assess whether to continue/postpone oocyte retrieval. | - Do screening questionnaire ± antigen testing - Positive patients/donors defer ART until completely recovered and not infectious. |
| **Fertility Society of Australia**<sup>41,42</sup> (24 Mar 2020) | - High-risk patients should consider cycle cancellation, oocyte and embryo freezing, and deferral of ET until complete recovery. | - Discuss appropriateness of postponing treatment. Any medical conditions warranting continuation of treatment? |
| **The Italian Society of Fertility and Sterility and Reproductive Medicine**<sup>43</sup> (Jun 2020) | - Defer in high-risk patients with pre-existing medical history such as renal, liver, or heart disease, diabetes mellitus, hypertension, or immunosuppressive conditions. - Prioritise urgent patients to start ART. Defer treatment for young patients undergoing ovulation induction for timed sexual intercourse and intrauterine insemination. | |

Abbreviations: ART = assisted reproductive technology; COVID-19 = coronavirus disease 2019; ESHRE = European Society of Human Reproduction and Embryology; ET = embryo transfer; Ig = immunoglobulin; OHSS = ovarian hyperstimulation syndrome; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
**TABLE 2  Infection control recommendation for assisted reproductive technology centres and laboratories**

<table>
<thead>
<tr>
<th>ART centres36,38,43,44,46-48</th>
<th>ART Laboratories36,38,43,44,46-48</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Telehealth (phone/video call): for symptom screenings/questionnaires, travel and close contact history, and all medical consultations where face-to-face meeting is not required.</td>
<td>- For cryopreservation of suspected/confirmed COVID-19-positive samples, store in separate high-security straws and/or vapour phase cryostorage tanks. Do not use Makler chamber/haemocytometer for COVID-19-positive samples.</td>
</tr>
<tr>
<td>- Advise male patients to produce semen samples at home before delivering them to laboratory.</td>
<td>- LN used for cryostorage can be contaminated with COVID-19. Use close system vitrification systems to avoid direct contact of embryos to LN and incorporate CBS high-security straws/other cryostorage systems. Alternatively, use sterile LN and vapour storage, UV sterilisation of LN, or sterile liquid air. For COVID-19 cases, use separate LN cryostorage systems.</td>
</tr>
<tr>
<td>- Screen patients' temperature and symptoms on arrival.</td>
<td>- All areas and equipment disinfected after each procedure. If any patient/staff member is positive, implement specific COVID-19 disinfection.</td>
</tr>
<tr>
<td>- Limit number of persons simultaneously in waiting rooms, with ≥1-m spacing between parties.</td>
<td>- Arrange staff into shift teams. If a staff member is infected, only one team has to undergo quarantine.</td>
</tr>
<tr>
<td>- Restrict access to chaperones. Request that patients wait in their vehicles until their appointment times.</td>
<td>- Revise emergency plans and arrange external embryologists for substitutes or refer patients to another ART centre in case all staff are quarantined.</td>
</tr>
<tr>
<td>- Use personal protective equipment, eye protection, masks, gloves, overshoes. Provide alcohol sanitiser.</td>
<td>- Train other personnel how to operate/refill cryobanks and handle cryopreserved specimens in case lab staff is quarantined.</td>
</tr>
<tr>
<td>- Assess air quality control by air filtration system and air pressurisation, particularly in laboratory.</td>
<td>- Minimise contact of laboratory staff with external personnel and patients.</td>
</tr>
<tr>
<td>- All areas regularly sanitised with alcohol-based disinfectant (≥75% alcohol or 5% chlorine).</td>
<td>- Avoid transporting cryopreserved specimens between centres.</td>
</tr>
</tbody>
</table>

Abbreviations: ART = assisted reproductive technology; COVID-19 = coronavirus disease 2019; LN = liquid nitrogen

Regarding fertility preservation, patients with cancer and inflammatory and autoimmune diseases should be given priority, as their treatments are gonadotoxic.43,47,48 Fertility preservation can only be done during the ‘remission window’, which is achieved after temporary discontinuation of therapy for 3 to 4 months.47,48 If those patients’ remission window coincided with the pandemic, they would have to either forego this ART opportunity and start gonadotoxic drugs again, meaning reduced ART success in future attempts as they age, or go without drugs for an extended period of time in the hopes of resuming fertility care. This would cause them to bear the risk of their medical conditions flaring up.48 Furthermore, the COVID-19 pandemic should be a novel indication for fertility preservation, especially in Poseidon groups 2 and 4.42

**Considerations for members of the general public who wish to undergo in vitro fertilisation**

Because of the lack of data and knowledge about SARS-CoV-2, it is imperative to discuss the uncertainties of COVID-19’s effects on fertility and ART with patients. Well-documented informed consent should be signed before commencing ART treatment. Patients should understand all the risks involved, including the risk of exposure at the ART clinic during treatment. In addition, it is important to counsel patients about the available options, from postponing to resuming treatment. Balancing should be done between the risks of deferring treatment in patients with low ART prognosis and those of undergoing treatment on fertility and pregnancy.47

The unknown effects of COVID-19 on pregnancy outcomes must also be discussed. Although there is no clear evidence of vertical transmission, it still cannot be ruled out.1,2,3,4,43,46,53,54 Immunosuppression and hormonal fluctuation during pregnancy leave women more vulnerable to respiratory pathogens and severe pneumonia.46 Nevertheless, a study revealed no higher susceptibility to COVID-19 in pregnant women than non-pregnant women.36 Further, pregnant women with COVID-19 do not have more severe symptoms than non-pregnant women.46,54

Despite the unclear pathogenesis of COVID-19 in pregnancy, it is associated with more maternal and fetal complications.46 These include preterm birth (most common), fetal distress, intrauterine growth restriction, and increase in Caesarean sections.46,54,56,57 Miscarriages and neonatal and maternal deaths have been reported, but no evidence has suggested that they are caused directly by COVID-19.46,54,56,57 Pre-existing co-morbidity in pregnant women with COVID-19 is associated with increased severity, higher intensive care unit admission, invasive ventilation, and neonatal unit admission of their newborns.46 These data are from women infected during the third trimester, and COVID-19’s effects during the first trimester are unknown.46,53,59

Patients with infertility face a high amount of stress, from fear of ART failure to uncertainty about the pandemic.43 Clinical and psychological support should be provided to advocate for patients’ well-being and to reduce treatment dropout.

**Conclusion**

Coronavirus disease 2019 has affected every part of the world, and it is likely to persist in the coming years. The potential risk of SARS-CoV-2
infection in the reproductive system and its effects on reproductive parameters and fertility cannot be ignored and warrant further quantitative research.

Shared decisions between doctors and patients should be made regarding fertility care. Patients' autonomy allows them to decide whether to resume or postpone treatment, but it is their doctors' responsibility to counsel them on all the risks and benefits involved. Individualisation of patients' ART treatment is the key to safe practice during this ongoing pandemic.

Author contributions
Concept or design: All authors.
Acquisition of data: WY Lee, A Mok.
Analysis or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: JPW Chung.

All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Conflicts of interest
As an editor of the journal, JPW Chung was not involved in the peer review process. Other authors have disclosed no conflicts of interest.

Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References